Multidrug resistance in leukemia

  • Danny Rischin
  • Victor Ling
Part of the Cancer Treatment and Research book series (CTAR, volume 64)


Over the last 20 years, advances in chemotherapy have improved the outcome in a number of cancers, most notably in the acute leukemias, lymphomas, testicular carcinoma, and several pediatric malignancies. Despite the advances in the treatment of the acute leukemias with very high remission rates to initial chemotherapy and significant cure rates, many patients will relapse and eventually become resistant to further chemotherapy [1,2]. Although several factors may contribute to the failure of chemotherapy, it is thought that a major obstacle is the development of drug resistance at the cellular level.


Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Multidrug Resistance Multi Drug Resistance Vinca Alkaloid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Champlin R, Gale RP (1987). Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562.PubMedGoogle Scholar
  2. 2.
    Champlin R, Gale RP (1989). Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 73: 2051–2066.PubMedGoogle Scholar
  3. 3.
    Biedler JL, Riehm H (1970). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 30: 1174–1184.PubMedGoogle Scholar
  4. 4.
    Dano K (1972). Cross resistance between Vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chemother Rep 56: 701–708.PubMedGoogle Scholar
  5. 5.
    Ling V, Thompson LH (1974). Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103–116.PubMedCrossRefGoogle Scholar
  6. 6.
    Juliano RL, Ling V (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152–162.PubMedCrossRefGoogle Scholar
  7. 7.
    Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A (1986). Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075–3081.PubMedGoogle Scholar
  8. 8.
    Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987). Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug-resistant human leukemic cells. Cancer Res 47: 5455–5460.PubMedGoogle Scholar
  9. 9.
    Mirski SEL, Gerlach JH, Cole SPC (1987). Multidrug resistance in a human small cell lung cancer line selected in adriamycin. Cancer Res 47: 2594–2598.PubMedGoogle Scholar
  10. 10.
    Slovak ML, Hoeltge GA, Dalton WS, Trent JM (1988). Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 48: 2793–2797.PubMedGoogle Scholar
  11. 11.
    Baas F, Jongsma APM, Broxterman HJ, Arceci RJ, Housman D, Scheffer GL, Riethorst A, Van Groenigen M (1990). Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 50: 5392–5398.PubMedGoogle Scholar
  12. 12.
    Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman M, Gottesman MM, Pastan I (1989). Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 81: 116–124.PubMedCrossRefGoogle Scholar
  13. 13.
    Chan H, Thorner PS, Haddad G, Ling V (1990). Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689–704.PubMedGoogle Scholar
  14. 14.
    Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuro-blastoma. N Engl J Med 325: 1608–1614.PubMedCrossRefGoogle Scholar
  15. 15.
    Georges E, Sharom FJ, Ling V (1990). Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 21: 185–220.PubMedCrossRefGoogle Scholar
  16. 16.
    Bradley G, Juranka PF, Ling V (1988). Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87–128.PubMedGoogle Scholar
  17. 17.
    Endicott JA, Ling V (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137–171.PubMedCrossRefGoogle Scholar
  18. 18.
    Veinot-Drebot L, Ling V (1990). The molecular biology of multidrug resistance. In Molecular Biology of Cancer Genes, Sluyser M (ed). Ellis Horword: Chichester, pp. 263–289.Google Scholar
  19. 19.
    Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB (1986). Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381–389.PubMedCrossRefGoogle Scholar
  20. 20.
    Van der Bliek AM, Kooiman PM, Schneider C, Borst P (1988). Sequence of mdr3 encoding a human P-glycoprotein. Gene 71: 401–411.PubMedCrossRefGoogle Scholar
  21. 21.
    Endicott JA, Juranka PF, Sarangi F, Gerlach JH, Deuchars KL, Ling V (1987). Simultaneous expression of two P-glycoprotein genes in drug-sensitive Chinese hamster ovary cells. Mol Cell Biol 7: 4075–4081.PubMedGoogle Scholar
  22. 22.
    Endicott J, Sarangi F, Ling V (1991). Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq 2: 89–101.PubMedGoogle Scholar
  23. 23.
    Gros P, Croop J, Housman D (1986). Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371–380.PubMedCrossRefGoogle Scholar
  24. 24.
    Gros P, Raymond M, Bell J, Housman D (1988). Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 8: 2770–2778.PubMedGoogle Scholar
  25. 25.
    Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V (1989). Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9: 1224–1232.PubMedGoogle Scholar
  26. 26.
    Bell DR, Trent JM, Willard HF, Riordan JR, Ling V (1987). Chromosomal location of human P-glycoprotein gene sequences. Cancer Genet Cytogenet 25: 141–148.PubMedCrossRefGoogle Scholar
  27. 27.
    Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V (1985). Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817–819.PubMedCrossRefGoogle Scholar
  28. 28.
    Roninson IB, Chin JE, Choi K, Gros P, Housman DE, Fojo A, Shen D-W, Gottesman MM, Pastan I (1986). Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538–4542.PubMedCrossRefGoogle Scholar
  29. 29.
    Scotto KW, Biedler JL, Melera PW (1986). Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232: 751–755.PubMedCrossRefGoogle Scholar
  30. 30.
    Bradley G, Naik M, Ling V (1989). P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 49: 2790–2796.PubMedGoogle Scholar
  31. 31.
    Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM (1986). Human multidrug-resistant cell lines: Increased mdrl expression can precede gene amplification. Science 232: 643–645.PubMedCrossRefGoogle Scholar
  32. 32.
    Hill BT, Deuchars K, Hosking LK, Ling V, Whelan RD (1990). Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 82: 607–612.PubMedCrossRefGoogle Scholar
  33. 33.
    Deuchars KL, Du R-P, Naik M, Evernden-Porelle D, Kartner N, Van der Bliek AM, Ling V (1987). Expression of hamster P-glycoprotein and multidrug resistance in DNA-mediated transformants of mouse LTA cells. Mol Cell Biol 7: 718–724.PubMedGoogle Scholar
  34. 34.
    Gros P, Neriah YB, Croop JM, Housman DE (1986). Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728–731.PubMedCrossRefGoogle Scholar
  35. 35.
    Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987). Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84: 3004–3008.PubMedCrossRefGoogle Scholar
  36. 36.
    Guild B, Mulligan RC, Gros P, Housman D (1988). Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci USA 85: 1595–1599.PubMedCrossRefGoogle Scholar
  37. 37.
    Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC (1988). A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci 85: 4486–4490.PubMedCrossRefGoogle Scholar
  38. 38.
    Schinkel AH, Roelofs MEM, Borst P (1991). Characterization of the human mdr3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 51: 2628–2635.PubMedGoogle Scholar
  39. 39.
    Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V (1986). Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324: 485–489.PubMedCrossRefGoogle Scholar
  40. 40.
    Juranka PF, Zastawny RL, Ling V (1989). P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3: 2583–2592.PubMedGoogle Scholar
  41. 41.
    Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelchak Z, Zielenski J, Lok S, Plavsik N, Chou J-L, Drumm ML, Iannuzzi MC, Collins FS, Tsui L-C (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073.PubMedCrossRefGoogle Scholar
  42. 42.
    Monaco JJ (1992). A molecular model of MHC class-1-restricted antigen processing. Immunol Today 13: 173–178.PubMedCrossRefGoogle Scholar
  43. 43.
    McGrath JP, Varshavsky A (1989). The yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-glycoprotein. Nature (Lond) 340: 400–404.CrossRefGoogle Scholar
  44. 44.
    Dano K (1973). Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466–483.PubMedCrossRefGoogle Scholar
  45. 45.
    See YP, Carlsen SA, Till JE, Ling V (1974). Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim Biophys Acta 373: 242–252.PubMedCrossRefGoogle Scholar
  46. 46.
    Horio M, Gottesman MM, Pastan I (1988). ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85: 3580–3584.PubMedCrossRefGoogle Scholar
  47. 47.
    Cornwell MM, Tsuruo T, Gottesman MM, Pastan I (1987). ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells. FASEB J 1: 51–54.PubMedGoogle Scholar
  48. 48.
    Hamada H, Tsuruo T (1988). Purification of the 170-to 180-Kilodalton membrane glyco-protein associated with multidrug resistance. J Biol Chem 263: 1454–1458.PubMedGoogle Scholar
  49. 49.
    Shimabuku AM, Nishimoto T, Ueda K, Komano T (1992). P-glycoprotein, ATP hydrolysis by the N-terminal nucleotide-binding domain. J Biol Chem 267: 4308–4311.PubMedGoogle Scholar
  50. 50.
    Azzaria M, Schurr E, Gros P (1989). Discrete mutations introduced in the predicted nucleotide-binding sites of the mdrl gene abolish its ability to confer multidrug resistance. Mol Cell Biol 9: 5289–5297.PubMedGoogle Scholar
  51. 51.
    Safa AR, Glover CJ, Meyers MB, Biedler JL, Felsted RL (1986). Vinblastine photo-affinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 261: 6137–6140.PubMedGoogle Scholar
  52. 52.
    Cornwell MM, Safa AR, Felsted RL, Gottesman MM, Pastan I (1986). Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150-to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 83: 3847–3850.PubMedCrossRefGoogle Scholar
  53. 53.
    Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson IB (1990). Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185-H→ Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 87: 7225–7229.PubMedCrossRefGoogle Scholar
  54. 54.
    Devine S, Ling V, Melera P (1992). Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 89: 4564–4568.PubMedCrossRefGoogle Scholar
  55. 55.
    Gros P, Dhir R, Croop J, Talbot F (1991). A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdrl and mouse mdr3 drug efflux pumps. Proc Natl Acad Sci USA 88: 7289–7293.PubMedCrossRefGoogle Scholar
  56. 56.
    Beck WT, Mueller TJ, Tanzer LR (1982). Continued expression of Vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer Res 42: 184–189.PubMedGoogle Scholar
  57. 57.
    Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR (1983). The multidrug resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67: 869–874.PubMedGoogle Scholar
  58. 58.
    Center MS (1983). Evidence that adriamycin resistance in Chinese hamster lung cells is regulated by phosphorylation of a plasma membrane glycoprotein. Biochem Biophys Res Commun 115: 159–166.PubMedCrossRefGoogle Scholar
  59. 59.
    Hamada H, Hagiwara K-I, Nakajima T, Tsuruo T (1987). Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 47: 2860–2865.PubMedGoogle Scholar
  60. 60.
    Endicott JA, Sarangi F, Georges E, Ling V (1991). P-glycoprotein phosphorylation and the multidrug resistance phenotype. Proc Am Assoc Cancer Res 32: 367.Google Scholar
  61. 61.
    Mellado W, Horwitz SB (1987). Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 26: 6900–6904.PubMedCrossRefGoogle Scholar
  62. 62.
    Chambers T, McAvoy EM, Jacobs JW, Eilon G (1990). Protein kinase C phosphorylates p-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265: 7679–7686.PubMedGoogle Scholar
  63. 63.
    Fine RL, Patel J, Chabner BA (1988). Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85: 582–586.PubMedCrossRefGoogle Scholar
  64. 64.
    Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T (1991). Transfection with protein kinase Ca confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3: 181–189.PubMedGoogle Scholar
  65. 65.
    Center MS (1985). Mechanisms regulating cell resistance to adriamycin: evidence that drug accumulation in resistant cells is modulated by phosphorylation of a plasma membrane glycoprotein. Biochem Pharmacol 34: 1471–1476.PubMedCrossRefGoogle Scholar
  66. 66.
    Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, Rosen N, Fojo AT (1989). Modulation of the expression of a multidrug resistance gene (mdr-1 /P-glycoprotein) by differentiating agents. J Biol Chem 264: 18031–18040.PubMedGoogle Scholar
  67. 67.
    Bates SE, Mickley LA, Chen Y, Richert N, Rudick J, Biedler JL, Fojo AT (1989). Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol Cell Biol 9: 4337–4344.PubMedGoogle Scholar
  68. 68.
    Bates SL, Currier SJ, Alvarez M, Fojo AT (1992). Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31: 6366–6372.PubMedCrossRefGoogle Scholar
  69. 69.
    Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM (1987). Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236: 1120–1122.PubMedCrossRefGoogle Scholar
  70. 70.
    Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers CE, Farber E, Cowan KH (1987). Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sei USA 84: 7701–7705.CrossRefGoogle Scholar
  71. 71.
    Bradley G, Sharma R, Rajalakshmi S, Ling V (1992). P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52: 5154–5161PubMedGoogle Scholar
  72. 72.
    Arceci RJ, Croop JM, Horwitz SB, Housman D (1988). The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 85: 4350–4354.PubMedCrossRefGoogle Scholar
  73. 73.
    Bradley G, Georges E, Ling V (1990). Sex dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol 145: 398–408.PubMedCrossRefGoogle Scholar
  74. 74.
    Axiotis CA, Guarch R, Merino MJ, Laporte N, Neumann RD (1991). P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest 65: 577–581.PubMedGoogle Scholar
  75. 75.
    Yang CH, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB (1989). Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782–788.PubMedGoogle Scholar
  76. 76.
    Naito M, Yuso K, Tsuruo T (1989). Steroid hormones inhibit binding of vinca alkaloid to multidrug resistance related P-glycoprotein. Biochem Biophys Res Commun 158: 1066–1071.PubMedCrossRefGoogle Scholar
  77. 77.
    Qian X-D, Beck WT (1990). Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. J Biol Chem 265: 18753–18756.PubMedGoogle Scholar
  78. 78.
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987). Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269.PubMedCrossRefGoogle Scholar
  79. 79.
    Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988). Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48: 1926–1929.PubMedGoogle Scholar
  80. 80.
    Thiebaut T, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735–7738.PubMedCrossRefGoogle Scholar
  81. 81.
    Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed M, Bertino J (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695–698.PubMedCrossRefGoogle Scholar
  82. 82.
    Georges E, Bradley G, Gariepy J, Ling V (1990). Detection of P-glycoprotein isoforms gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87: 152–156.PubMedCrossRefGoogle Scholar
  83. 83.
    Goldberg H, Ling V, Wong PY, Skorecki K (1988). Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 152: 552–558.PubMedCrossRefGoogle Scholar
  84. 84.
    Sharma RS, Inoue S, Toitelman J, Schimke RT, Simoni RD (1992). Peptide transport by the multidrug resistance pump. J Biol Chem 267: 5731–5734.PubMedGoogle Scholar
  85. 85.
    Raymond M, Gros P, Whiteway M, Thomas DY (1992). Functional complementation of yeast STE6 by a mammalian multidrug resistance mdr gene. Science 56: 232–233.CrossRefGoogle Scholar
  86. 86.
    Valverde MA, Diax M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF (1992). Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 355: 830–833.PubMedCrossRefGoogle Scholar
  87. 87.
    Chaudhary PM, Roninson IB (1991). Expression and activity of P-glycoprotein, a multi-drug efflux pump, in human hematopoietic stem cells. Cell 66: 85–94.PubMedCrossRefGoogle Scholar
  88. 88.
    Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V (1985). Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J Clin Oncol 3: 311–315.PubMedGoogle Scholar
  89. 89.
    Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM (1987). P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J Clin Oncol 5: 1452–1460.PubMedGoogle Scholar
  90. 90.
    Herweijer H, Sonneveld P, Baas F, Nooter K (1990). Expression of mdrl and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 82: 1133–1140.PubMedCrossRefGoogle Scholar
  91. 91.
    Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff D, Roninson IB (1990). Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160–7164.PubMedCrossRefGoogle Scholar
  92. 92.
    Chan HSL, Bradley G, Thorner PS, Haddad G, Gallie BL, Ling V (1988). A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest 59: 870–875.PubMedGoogle Scholar
  93. 93.
    Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S (1990). Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63: 815–824.PubMedGoogle Scholar
  94. 94.
    Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985). Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820–823.PubMedCrossRefGoogle Scholar
  95. 95.
    Hamada H, Tsuruo T (1986). Functional role for the 170-to 180-kDA glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785–7789.PubMedCrossRefGoogle Scholar
  96. 96.
    Scheper RJ, Bulte JWM, Brakkee JGP, Quak JJ, van der Schoot E, Balm AJM, Meijer CJLM, Broxterman J, Kuiper CM, Lankelma J, Pinedo HM (1988). Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 42: 389–394.PubMedCrossRefGoogle Scholar
  97. 97.
    Meyers MB, Rittmann-Grauer L, O’Brien JP, Safa AR (1989). Charactertization of monoclonal antibodies recognizing an Mr 180,000 P-glycoprotein: differential expression of the Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res 49: 3209–3214.PubMedGoogle Scholar
  98. 98.
    Epstein J, Xiao H, Oba BK (1989). P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74: 913–917.PubMedGoogle Scholar
  99. 99.
    Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79: 473–476.PubMedGoogle Scholar
  100. 100.
    Ling V, Bradley G, Veinot LM, Hiruki T, Georges E (1992). Expression of P-glycoprotein isoforms. In Bristol-Myers Squibb Cancer Symposia 13, Tsuruo T, Ogawa M (eds). Academic Press: San Diego, pp. 117–128.Google Scholar
  101. 101.
    Nooter K, Sonnevold P, Oostrum R, Herweijer H, Hagenbeek T, Valerio T (1990). Overexpression of the mdrl gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin A. Int J Cancer 45: 263–268.PubMedCrossRefGoogle Scholar
  102. 102.
    Tapiero H, Munck J-N, Fourcade A, Lampidis TJ (1984). Cross-resistance to rhodamine 123 in adriamycin-and daunorubicin-resistant Friend leukemia cell variants. Cancer Res 44: 5544–5549.PubMedGoogle Scholar
  103. 103.
    Lalande ME, Ling V, Miller RG (1981). Hoechst 3334 dye uptake as a probe of membrane permeability changes in mammalian cells. Proc Natl Acad Sci USA 78: 363–367.PubMedCrossRefGoogle Scholar
  104. 104.
    Wall DM, Hu XF, Zalcberg JR, Parkin JD (1991). Rapid functional assay for multidrug resistance in human tumor cell lines using the fluorescent indicator Fluo-3. J Natl Cancer Inst 83: 206–207.PubMedCrossRefGoogle Scholar
  105. 105.
    Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 75: 340–345.PubMedCrossRefGoogle Scholar
  106. 106.
    Pirker R, Wallner J, Geissler K, Linkesh W, Haas OA, Bettelheim P, Hopfner M, Scherrer R (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712.PubMedCrossRefGoogle Scholar
  107. 107.
    Ma DD, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR (1987). Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet 1: 135–137.PubMedCrossRefGoogle Scholar
  108. 108.
    Ball ED, Lawrence D, Malnar M (1990). Correlation of CD34 and multi-drug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 76: 252a.Google Scholar
  109. 109.
    Marie J-P, Zittoun R, Sikic BI (1991). Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592.PubMedGoogle Scholar
  110. 110.
    Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M (1990). Expression of the multidrug transporter, P-glycoprotein in acute leukemia cells and correlation to clinical drug resistance. Cancer 66: 868–873.PubMedCrossRefGoogle Scholar
  111. 111.
    Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M (1991). High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77: 50–53.PubMedCrossRefGoogle Scholar
  112. 112.
    Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA (1988). Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72: 40–44.CrossRefGoogle Scholar
  113. 113.
    List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R, Sandberg AA (1991). Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 78: 28–34.PubMedCrossRefGoogle Scholar
  114. 114.
    Willman CL, Kopecky K, Griffith B, Chen IM, Noonan K, Roninson I, Head DR, Tsuruo T (1991). Multiparameter analysis of the expression of the multidrug resistance genes MDR1 and MDR2 (MDR3) in de novo AML by polymerase chain reaction (PCR) and multicolor flow cytometry: identification of a biological subset of CD34+, MDR1+ AML cases. Blood 78: 172a.Google Scholar
  115. 115.
    Haber DA (1992). Multidrug resistance (MDR1) in leukemia: Is it time to test? Blood 79: 295–298.PubMedGoogle Scholar
  116. 116.
    Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo AT (1989). Expression of the mdr-l/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74: 1388–1395.PubMedGoogle Scholar
  117. 117.
    Pieters R, Hongo T, Loonen AH, Huismans DR, Broxterman HJ, Hahlen K, Veerman AJP (1992). Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer 65: 691–697.PubMedCrossRefGoogle Scholar
  118. 118.
    Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T, Utsunomiya A, Ishibashi K, Saito T (1990). Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76: 2065–2071.PubMedGoogle Scholar
  119. 119.
    Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K, Morishima Y, Ohno R (1987). Detection of multidrug resistance markers, P-glycoprotein and mdrl mRNA, in human leukemia cells. Gann 78: 1415–1419.PubMedGoogle Scholar
  120. 120.
    Pirker R, Goldstein LJ, Ludwig H, Linkesch W, Lechner C, Gottesman MM, Pastan I (1989). Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Commun 1: 141–144.PubMedGoogle Scholar
  121. 121.
    Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler D (1990). Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res 14: 11–22.PubMedCrossRefGoogle Scholar
  122. 122.
    Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K, Utsunomiya A, Arima T (1990). Expression of the multidrug transporter, P-glycoprotein in chronic myelogenous leukaemia cells in blast crisis. Br J Haematol 74: 24–29.PubMedCrossRefGoogle Scholar
  123. 123.
    Weide R, Dowding C, Paulsen W, Goldman J (1990). The role of the MDR-l/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Leukemia 4: 695–699.PubMedGoogle Scholar
  124. 124.
    Carulli G, Petrini M, Maini A, Ambrogi F (1988). P-glycoprotein in acute nonlympho-blastic leukemia and in the blastic crisis of myeloid leukemia. N Engl J Med 319: 797–798.PubMedGoogle Scholar
  125. 125.
    Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich E (1988). Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 2: 157–164.PubMedGoogle Scholar
  126. 126.
    Liepman M, Votaw ML (1978). The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 41: 1664.PubMedCrossRefGoogle Scholar
  127. 127.
    Holmes JA, Jacobs A, Carter G, Whittaker JA, Bentley DP, Padua RA (1990). Is the mdr 1 gene relevant in chronic lymphocytic leukemia? Leukemia 4: 216–218.PubMedGoogle Scholar
  128. 128.
    Cumber PM, Jacobs A, Hoy T, Fischer J, Whittaker JA, Tsuruo T, Padua RA (1990). Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. Br J Haematol 76: 226–230.PubMedCrossRefGoogle Scholar
  129. 129.
    Shustik C, Groulx N, Gros P (1991). Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 79: 50–56.PubMedCrossRefGoogle Scholar
  130. 130.
    Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C, Michelutti A, Fanin R, Fasola G (1991). The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br J Haematol 77: 460–465.PubMedCrossRefGoogle Scholar
  131. 131.
    Perri RT, Piganto K, Johnson K (1991). Expression of the multidrug resistance (MDR) genes MDR1 and MDR2 in chronic lymphocytic leukemia (CLL) B cells. Blood 78: 33a.Google Scholar
  132. 132.
    Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer H, Valerio D, Hagemeijer A, Baas F (1990). Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 45: 626–631.PubMedCrossRefGoogle Scholar
  133. 133.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972.PubMedGoogle Scholar
  134. 134.
    Ford JM, Hait WN (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199.PubMedGoogle Scholar
  135. 135.
    Cornwell MM, Pastan I, Gottesman MM (1987). Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166–2170.PubMedGoogle Scholar
  136. 136.
    Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL (1987). Identification of the multidrug resistance-related membrance glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884–7888.PubMedGoogle Scholar
  137. 137.
    Akiyama S-I, Cornwell MM, Kuwano M, Pastan I, Gottesman MM (1988). Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 33: 144–147.PubMedGoogle Scholar
  138. 138.
    Foxwell BMJ, Mackie A, Ling V, Ryffel B (1989). Identification of the multi-drug resistance related, P-glycoprotein as a cyclosporine binding protein. Biochim Biophys Acta 36: 543–546.Google Scholar
  139. 139.
    Tamai I, Safa AR (1990). Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 265: 16509–16513.PubMedGoogle Scholar
  140. 140.
    Naito M, Tsuruo T (1989). Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 49: 1452–1455.PubMedGoogle Scholar
  141. 141.
    Tamai I, Safa AR (1991). Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266: 16796–16800.PubMedGoogle Scholar
  142. 142.
    Zamora JM, Pearce HL, Beck WT (1988). Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454–462.PubMedGoogle Scholar
  143. 143.
    Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I (1991). Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88: 547–551.PubMedCrossRefGoogle Scholar
  144. 144.
    Coley HM, Twentyman PR, Workman P (1990). 9-alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer 26: 665–667.PubMedCrossRefGoogle Scholar
  145. 145.
    Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen G (1992). Reversal of vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 52: 1810–1816.PubMedGoogle Scholar
  146. 146.
    Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, Riggs CW, Komschlies K (1991). Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 83: 1386–1391.PubMedCrossRefGoogle Scholar
  147. 147.
    Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE (1989). Drug resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424.PubMedGoogle Scholar
  148. 148.
    Sonneveld P, Nooter K (1990). Reversal of drug resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 75: 208–211.PubMedCrossRefGoogle Scholar
  149. 149.
    List AF, Spier CM, Greer JP, Azar CA, Hutter JJ, Wolff SN, Salmon SE, Futscher BF (1991). Circumvention of P-glycoprotein (PGP) mediated anthracycline resistance in acute myeloid leukemia (AML) with cyclosporin-A (CSA). Blood 78: 47a.Google Scholar
  150. 150.
    Thierry AR, Jorgensen TJ, Forst D, Belli JA, Dritschilo A, Rahman A (1989). Multidrug resistance in Chinese hamster cells: effect of liposome-encapsulated doxorubicin. Cancer Commun 1: 311–316.PubMedGoogle Scholar
  151. 151.
    Mickisch GH, Rahman A, Pastan I, Gottesman M (1992). Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 84: 79–80.CrossRefGoogle Scholar
  152. 152.
    Fitzgerald DJ, Willingham MC, Cardarelli CO, Hamada H, Tsuruo T, Gottesman MM, Pastan I (1987). A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84: 4288–4292.PubMedCrossRefGoogle Scholar
  153. 153.
    Vasanthakumar G, Ahmed NK (1989). Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Cancer Commun 1: 225–232.PubMedGoogle Scholar
  154. 154.
    McLachlin JR, Eglitis MA, Ueda K, Kantoff PW, Pastan IH, Anderson WF, Gottesman MM (1990). Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 82: 1260–1263.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Danny Rischin
  • Victor Ling

There are no affiliations available

Personalised recommendations